Study at Pennington Biomedical Research Center to evaluate THC, CBD benefits for dementia-related agitation

Pennington Biomedical currently recruiting hospice-eligible dementia patients “LiBBY” research stud

2024-09-04

(Press-News.org) Pennington Biomedical Research Center’s Dr. Jeff Keller is evaluating the potential for delta-9-tetrahydrocannabinol, or THC, and cannabidiol, or CBD, to reduce the behaviors indicating agitation, distress or anxiety in patients with Alzheimer’s disease or other forms of dementia. The study is designed for hospice-eligible patients who are either receiving hospice care or who are eligible for hospice, and who are exhibiting agitation concurrently with a diagnosis of dementia. There are currently no FDA-approved medications to treat agitation at the end-of-life stages in dementia patients.

The “Life’s End Benefits of Cannabidiol and Tetrahydrocannabinol” or LiBBY, study is the first-of-its-kind national study funded by the National Institute of Aging. The placebo-controlled, double-blinded study is designed to help researchers further explore these compounds for their potential to ease the burden of patients and caregivers.

“The restlessness, anxiety, and distress that frequently accompanies Alzheimer’s and dementia can be frustrating and frightening for both the patient and their caregivers,” said Dr. Keller, who is the director of Institute for Dementia Research & Prevention at Pennington Biomedical and a professor of aging and neurodegeneration. “The LiBBY study intends to explore whether THC and CBD can be safe and effective options for managing agitation in dementia patients. This landmark, multisite study will increase the pace of THC clinical research nationwide, and Pennington Biomedical’s participation makes it much easier to initiate THC research at this facility in the future.”

Upon joining the study, participants will complete a baseline visit and will be randomly assigned to one of two study groups: one receiving the active study drug, and one receiving a placebo. The active study will last for 12 weeks and will include one screening visit, six in-person visits, and five evaluations by phone.

Before the study concludes, all participants will have the opportunity to request to continue their participation in the “Open Label Extension” portion of the study. Though participants will not know if they are receiving the study drug or the placebo during the study, all participants will receive the active study drug in the “Open Label Extension” period.

“Dementia, especially when coupled with agitation, can be frightening for patients and heartbreaking for caregivers, who frequently face burnout. As other studies have shown THC can help in treating post-chemotherapy nausea, the LiBBY study is a practical next step in exploring the benefits of these compounds and offering hope to those facing this difficult challenge,” said Dr. John Kirwan, Executive Director of Pennington Biomedical. “Dr. Keller and his colleagues have worked incredibly diligently to bring this study to Pennington Biomedical. We are proud to have this study here and to have it position the Center for similar studies in the future.”

Pennington Biomedical is one of 11 research institutions to facilitate the LiBBY study and exploring the use of THC for dementia-related agitation. Pennington Biomedical, Georgetown University Medical Center, the University of Kentucky, and the Ralph H. Johnson VA Medical Center are currently recruiting participants.

The research facility is working with hospice care providers in Capital Region and beyond to share the details of this study with patients and their families. Carpenter Health network, a large Baton Rouge-based hospice group, is one of the care providers to help identify patients and caretakers who may be eligible for the study.

"The Carpenter Health Network is proud to join with other late-stage care facilities and networks to share this study with the families we work with daily," said Raoul Manalac, Medical Director at St. Joseph Hospice – Baton Rouge. "Dementia is accompanied by many challenges, with agitation and anxiety among the most frightening and frustrating for patients and families, and there are few options available to provide relief. This innovative study is driven by both the quest for new knowledge, as well as compassion for families dealing with dementia.”

Hospice groups and end-of-life care providers in South Louisiana will be instrumental connecting eligible patients with the study. Those providers or groups who are interested can contact Dr. Jeff Keller at jeffrey.keller@pbrc.edu.

About the Pennington Biomedical Research Center

The Pennington Biomedical Research Center is at the forefront of medical discovery as it relates to understanding the triggers of obesity, diabetes, cardiovascular disease, cancer and dementia. The Center conducts basic, clinical, and population research, and is a campus of the LSU System. The research enterprise at Pennington Biomedical includes over 530 employees within a network of 44 clinics and research laboratories, and 13 highly specialized core service facilities. Its scientists and physician/scientists are supported by research trainees, lab technicians, nurses, dietitians, and other support personnel. Pennington Biomedical is a state-of-the-art research facility on a 222-acre campus in Baton Rouge. For more information, see www.pbrc.edu.

END

ELSE PRESS RELEASES FROM THIS DATE:

Illinois scientists to test modernized genetic model for optimized crop breeding

2024-09-04

URBANA, Ill. — The National Science Foundation (NSF) has funded University of Illinois Urbana-Champaign research that aims to connect the dots between quantitative and molecular genetics and improve crop breeding. The four-year, $795,000 grant investigates new theories on how genetics influence complex crop traits, such as yield or grain quality. These traits are controlled by lots of different genes — sometimes hundreds or thousands — which makes untangling their contributions difficult. Crop breeders use a host of advanced genetic tools to predict and ...

Adolescent glioma subtype responds to CDK4/6 inhibitor

2024-09-04

Boston – CDK4/6 inhibitors, which are already FDA approved for the treatment of other forms of cancer, show early signs of promise in the treatment of a subtype of pediatric high-grade glioma, according to new research from Dana-Farber Cancer Institute and the Institute of Cancer Research in London. Treatment of a patient with a second relapse of this glioma subtype and no other treatment options resulted in 18 months of progression-free survival. “We are finally starting to see more targeted therapies come out for different forms of brain cancer,” says senior author Mariella Filbin, MD, PhD, co-director ...

Study highlights importance of social media influencers in information dissemination during mpox outbreak

2024-09-04

A recent study shows social media influencers are more important than previously thought when it comes to getting out vital information in a crisis. The study suggested partnerships that could improve public communication between governments, non-profits and social media influencers during crises. The study, conducted by UF/IFAS assistant professor Kimberly Kay Wiley, a researcher in the family, youth and community sciences department, and Bridgewater State University associate professor Seth Meyer, shows how these groups can collaborate to effectively disseminate information and manage public health emergencies on social media. “In ...

Ability to cope well with adversity in older age linked to lower death risk

2024-09-04

The ability to cope well with, and adapt to, challenging life circumstances and events in older age is linked to a lower risk of death, suggests a large nationally representative study, published in the open access journal BMJ Mental Health. The findings underscore the importance of efforts to bolster mental resilience, conclude the researchers. The available evidence suggests that mental resilience is a dynamic and active process influenced by various factors, including sex, hormones, and the genes regulating ...

Number of general practices shrinking but patient lists ballooning in England

2024-09-04

Over the past decade the number of NHS general practices in England has shrunk by 20%, but patient list sizes have expanded by 40% to just under 10,000, on average, finds an analysis of three national primary care datasets, published in the open access journal BMJ Open. And while the total NHS general practice workforce grew 20% between 2015 and 2022, as a result of increases in admin staff and other practitioners, the number of GPs per 1000 patients fell by 15% over the same period, when accounting for working hours, the analysis shows. Major structural and organisational changes have taken place in general practice in England over the past decade,but it’s difficult ...

Women, Black people, and disadvantaged less likely to get heart surgery in England

2024-09-04

Women, people of Black ethnicity, and those from low income households in England are less likely to be offered heart surgery than men, White people, and those who are affluent, finds research published online in the journal Heart. And when they do have these procedures, they are more likely to die within a year, prompting the researchers to call for prompt action to tackle these health inequalities. Cardiac surgery is one of the costliest ways of treating cardiovascular disease, with around 28,000 adults a year in the UK undergoing the procedure, note the researchers. While previously published research shows that gender, ethnicity, and social/economic deprivation can affect ...

A sensory pen which can read Braille could improve literacy amongst the visually impaired

2024-09-04

A pen which can transform Braille into English text has been developed by experts at the University of Bristol. Braille literacy is frequently reported as being in decline, this is despite visually impaired people often expressing a desire to learn it, and Braille literacy being a highly valued skill by those who are capable. This is often attributed to the lack of available learning resources, particularly away from large urban centres. The handheld device, which includes a one-centimetre sensor with 19 channels programmed to read Braille, has demonstrated high accuracy in early trials. Lead author Dr George Jenkinson ...

AI tool offers more accurate detection of immune-related adverse events in cancer patients

2024-09-04

While immune checkpoint inhibitors (ICIs) can provide lifesaving treatment for patients with cancer, they have also been found to cause immune-related adverse events (irAEs) — side effects that can impact almost every organ in the body to varying degrees. The frequency and severity of irAEs in real-world datasets are not well understood, making it difficult to combine cases effectively across institutions and gain insights into the optimal management of these patients. Since current approaches to investigate irAEs are done manually and are inefficient, researchers from Mass General Brigham have incorporated the use of a prebuilt large language ...

Applications open for ISSCR Lawrence Goldstein Science Policy Fellowship

2024-09-03

The ISSCR is accepting applications through 25 October 2024 for the next class of Lawrence Goldstein Science Policy Fellows. The three-year program offers fellows advocacy and public policy training, the opportunity to participate in ISSCR advocacy events, engagement with leaders in the field, and an ex officio seat on ISSCR’s Public Policy Committee. Goldstein Policy Fellows also have the opportunity to: Attend ISSCR’s Congressional Advocacy Day in Washington D.C. or a policy- related event in another region of the world. Participate in regularly scheduled Public Policy Committee meetings. Assist the committee and ISSCR policy staff with projects and programs. Contribute ...

UT Health San Antonio appoints alumnus as new executive director of Mays Cancer Center

2024-09-03

Lei Zheng, MD, PhD, alumnus of The University of Texas Health Science Center at San Antonio (UT Health San Antonio), has been appointed executive director of Mays Cancer Center at UT Health San Antonio and vice president for oncology for the health science center, effective Sept. 1, 2024. Zheng will also be named the Mays Family Foundation Distinguished University Presidential Chair of Oncology and appointed as a professor with tenure in the Department of Medicine at UT Health San Antonio’s ...

LAST 30 PRESS RELEASES:

Sexual health symptoms may correlate with poor adherence to adjuvant endocrine therapy in Black women with breast cancer

Black patients with triple-negative breast cancer may be less likely to receive immunotherapy than white patients

Affordable care act may increase access to colon cancer care for underserved groups

UK study shows there is less stigma against LGBTQ people than you might think, but people with mental health problems continue to experience higher levels of stigma